Amgen (AMGN) PT Raised to $362 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Stocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
August 7, 2024 5:03 AM EDTStocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
... MoreWells Fargo Downgrades Amgen (AMGN) to Equal Weight
August 7, 2024 3:33 AM EDTWells Fargo analyst Mohit Bansal downgraded Amgen (NASDAQ: AMGN) from Overweight to Equal Weight with a price target of $335.00 (from $320.00).
The analyst comments: "We are downgrading AMGN to Equal Weight with $335/sh PT because we think the Street is already giving them... More
Amgen quarterly profit slips, obesity data on track for late 2024
August 6, 2024 4:05 PM EDTBy Deena Beasley
(Reuters) -Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses, including costs related to development of its experimental obesity drug MariTide, offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
Amgen reported adjusted earnings of $4.97 per share, which was 3 cents shy of the average analyst estimate, according to LSEG data.
Quarterly revenue of $8.39 billion was slightly ahead of the $8.37 billion forecast by analysts.
"The quarter overall looks fairly uneventful," Mizuho... More
Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance
August 6, 2024 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q2 EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39 billion versus the consensus estimate of $8.35 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $19.10-$20.10, versus the consensus of $17.87. Amgen sees... More
